The facility, which is currently under construction, is slated for completion in the fourth quarter of 2022. It will house the company's new global headquarters and will include multiple good manufacturing practice suites for manufacturing RNA therapeutics.

PNI's new facility will include a new genetic medicine biomanufacturing center partially funded with a grant of $25.1 million Canadian dollars ($20.1 million U.S.) from Canada's Strategic Innovation Fund to support the country's efforts for future pandemic preparedness through the manufacture of RNA vaccines, PNI said.

Heat Biologics breaks ground on San Antonio biomanufacturing facility
Heat Biologics has broken ground for a new biomanufacturing facility in San Antonio.

Cytiva, Pall to invest $1.5B in biomanufacturing over next 2 years
Cytiva and Pall, both Danaher companies, will make major investments in manufacturing capacity and services at 13 sites around the globe supporting life...

Bio-Techne opens new facility in Ireland
Bio-Techne has opened a new facility in Dublin as part of its efforts to support the life sciences industry in Europe.

Danaher acquires Precision NanoSystems
Danaher has acquired Precision NanoSystems, a Canadian developer of genetic medicines including messenger RNA vaccines.

Precision NanoSystems launches T-cell kits for mRNA-lipid nanoparticles
Precision NanoSystems has launched its GenVoy-ILM T Cell Kit for messenger RNA (mRNA) to enable lipid nanoparticle-based ex vivo gene transfer.